Every 10-Q that Syndax Pharmaceuticals, Inc. (SNDX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SNDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SNDX filings page.
Syndax Pharmaceuticals reported strong top-line growth for the quarter and six months ended June 30, 2026, driven by its two approved oncology medicines. Revuforj generated $54.7 million in Q2 2026 net revenue, while Syndax’s share of Niktimvo’s U.S. profit produced $18.1 million of collaboration revenue; management noted Niktimvo net revenue of $60.3 million in the quarter.
For the first half of 2026, Revuforj product revenue reached $103.6 million and collaboration revenue from Niktimvo was $34.0 million. The company’s net loss for the six‑month period narrowed to $92.0 million from $156.7 million a year earlier, as higher revenues offset continued research, development and commercialization spending.
Liquidity remains a focus. As of June 30, 2026, Syndax held $575.1 million in cash, cash equivalents and short‑ and long‑term investments. The capital structure includes a $350.0 million Royalty Pharma funding tied to Niktimvo U.S. sales and $250.0 million of 2.25% Convertible Senior Notes due 2031, alongside ongoing investment in an expanding late‑stage and early‑stage pipeline.
Syndax Pharmaceuticals reported strong Q1 2026 growth but remained unprofitable. Total revenue reached $64.9 million, more than triple the $20.0 million reported a year earlier, driven by new cancer medicines Revuforj and Niktimvo.
Revuforj net product revenue was $48.9 million, up sharply as additional indications and greater physician adoption took hold. Collaboration revenue from Niktimvo contributed $15.9 million as its U.S. launch matured. Operating expenses fell modestly to $99.1 million, reflecting lower launch and milestone costs, while research and development spending remained high to fund multiple late‑stage trials.
Syndax narrowed its net loss to $42.7 million from $84.8 million a year earlier, helped by higher sales but partly offset by $11.8 million of royalty interest expense tied to its Royalty Pharma financing. Cash, cash equivalents and short‑term investments totaled $352.1 million as of March 31, 2026, supporting continued commercialization and development plans.
Syndax Pharmaceuticals (SNDX) reported Q3 2025 results. Total revenue reached $45.9 million, driven by $32.0 million in Revuforj product sales and $13.9 million in Niktimvo collaboration revenue. The company posted a net loss of $60.7 million (basic and diluted EPS $(0.70)), reflecting continued investment in commercialization and development.
Operating expenses were $103.3 million, including $56.3 million in R&D and $44.9 million in SG&A. Cash, cash equivalents, and short- and long‑term investments totaled $456.1 million at quarter end, with inventory of $25.0 million. A royalty interest financing liability related to Niktimvo stood at $343.9 million (net).
Year‑to‑date through September 30, revenue was $103.6 million and net loss $217.4 million. Subsequent to quarter end, the FDA approved Revuforj on October 24, 2025 for R/R AML with an NPM1 mutation, and Revuforj was added to the NCCN Guidelines for AML on September 18, 2025.